In IBS, where mucosal immune alterations can contribute to symptom generation, targeting such GPCR pathways (for example, enhancing FFAR2 signaling with SCFAs or modulating GLP-1R) may restore immune homeostasis. The gene discussed is MRGPRX1; the disease is irritable bowel syndrome.